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Validation of a predictive model of idiopathic membranous nephropa-
thy: Its clinical and research implications. Although a number of factors
have consistently correlated with progression to chronic renal insufficiency
(CR!) in idiopathic membranous glomerulonephropathy (IMGN), they
appear late, are not quantitative in nature and have not been validated.
We have determined that the highest sustained six-month period of
proteinuria is an important predictor of progression. Using multiple
logistic modelling, the only additional prognostic variables of importance
in 184 Canadian patients were the initial creatinine clearance and the rate
of change in function over this six-month interval. Independent data from
Italy (101 patients) and Finland (78 patients) were obtained for compar-
ison. Sensitivity, specificity, negative and positive predictive values and
overall accuracy, as well as Pearson's goodness-of-fit and Harrell's "C"
statistic were used to assess the fits of the model. Accuracy of prediction
was  85% in all three countries. Pearson's Chi-square goodness-of-fit
showed good agreement across the spectrum and Harrell's "C" statistic
was  90%. Therefore, a predictive, semiquantitative algorithm in IMGN
has been validated. Its relevance in patient management and in clinical
trials is illustrated.
Accurately predicting outcome early in the course of the patient
with idiopathic menibranous nephropathy remains a major prob-
lem in clinical nephrology. This disorder is the most common form
of adult onset nephrotic syndrome, and despite numerous papers
indicating the natural history and the parameters that can be used
to predict outcome, the factors have been qualitative rather than
quantitative and the conclusions reached often contradictory
[1—8]. The ability to provide an accurate prognosis has been
further complicated by suggested differences in outcomes attrib-
utable to race, gender, age, geography and even molecular
genotype [9—21]. These factors, in turn, have led to limited
utilization of these predictive factors and to contrary opinions
about who and when to treat [22, 23]. Each study generates
editorials that ask questions related to the risk versus benefits of
these contrasting approaches [24, 25]. Analyses of predictor
variables have become sophisticated in the last decade and have
included both multivariate proportional hazards and logistic mod-
els [12, 26, 27], and although these studies have clearly illustrated
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the weaknesses of single cross sectional predictors of outcome,
they have not provided a method of quantitating the risk of
progression for individuals or to groups of patients with the
disease. None of the prognostic parameters have been validated.
We have previously described a model which predicted outcome
in a semiquantitative fashion in patients with membranous ne-
phropathy [28]. The basic tenet of using persistence of certain
levels of proteinuria over time has been supported by other
authors based on retrospective reviews [26, 29]. However, major
concerns have been expressed related to our model's complexity,
the variations in the duration of observation required, and
whether the results have a general application since the model was
derived from a single Canadian center [25]. The major clinical
criticism has been that the required prolonged observation time in
some patients might delay treatment beyond the point where it is
most beneficial.
We addressed these questions by redoing the probability mod-
eling on our data using a single, short six-month time frame and
by obtaining two large, geographically and clinically distinct
databases of patients with IMGN in order to validate the algo-
rithm.
Methods
The initial database was obtained from the Metropolitan To-
ronto Glomerulonephritis Registry, which has been in existence
since 1974. The city's nephropathologists forward a copy of all
biopsy data on patients with glomerulonephritis to the Registry
[30]. Initial clinical and laboratory data on these patients and all
subsequent follow-ups at two to six month intervals are collected
and the information entered into an on-site computer database.
This database reflects the regional experience of 18 community
and university teaching hospitals in Toronto, with a population
base of approximately 4.5 million.
In our initial model, 184 patients were selected out of 272 cases
of membranous glomerulonephritis in the Registry. The 88 ex-
cluded patients were identified as having a secondary cause or less
than 12 months of observation (68 cases) or renal insufficiency at
presentation (20 cases). One independent database was obtained
from the Italian Idiopathic Membranous Nephropathy Study
group. The 110 patients from 12 hospitals in northern Italy have
participated in a number of collaborative clinical trials in this
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disorder. This particular database represents an unselected pop-
ulation of patients with membranous nephropathy gathered con-
tinuously over a three year period. All patients had idiopathic
disease and a minimum of one year of follow-up, and had clinical
assessments and renal function tests collected prospectively at
six-month intervals. These data were transferred to the Toronto
center without further editing. The second database was obtained
from Helsinki University in Finland. This consisted of 84 patients
whose clinical and laboratory data confirmed idiopathic membra-
nous nephropathy. Information on their clinical course had also
been documented at one to six month intervals.
The only subsequent selection was to apply the same criteria to
these two data sets as we did in our index set, that is, any patient
at presentation or within six months that had a consistent creati-
nine clearance < 60 ml/min/1.73 m2 was excluded since our
objective was to validate the algorithm's capacity to predict this
particular event. This editing removed nine patients from the
Italian data set and five patients from the Finnish group. One
other Finnish patient, who had only one month of follow-up, was
also excluded.
Definitions
Chronic renal insufficiency (CR1) was identified by a creatinine
clearance of < 60 mllminll.73 m2 that persisted for at least 12
months. End-stage renal disease (ESRD) was defined by the point
when the patient required renal transplantation, dialysis, or the
creatinine value was  9 mgldl. Nephrotic syndrome was protein-
uria  3.5 g/day, and complete remission was proteinuria of < 0.3
day with a stable or improving creatinine clearance (Car). The
rate of change in function was defined as the slope of the Cr over
time in mls/min/1.73 m2 X (months)'. Hypertension was consid-
ered as present if the sitting diastolic blood pressure was  90 mm
Hg or the patient was on antihypertensive medications. Control
was labeled good if the diastolic pressure was < 90 mm Hg during
at least 80% of the patient's subsequent visits, and poor if diastolic
pressure was  90 mm Hg during at least 80% of the follow-up
visits. The remaining patients were classified as mild hyperten-
sives.
Method of study
The demographic data and renal function parameters from all
three countries were entered into our standardized glomerulone-
phritis database [30]. We selected the interval of worst sustained
proteinuria by examining all possible time periods of approxi-
mately six months length in each patient's follow-up. In each such
interval we found the minimum 24-hour proteinuria value ( 2
estimates per period), and referred to it as the sustained protein-
uria level for that six-month period. If, for example, a patient had
proteinuria that was never lower than 4 g/day in a six month
interval, then 4 g would be the level attached to that time frame.
Then, looking at all possible intervals prior to CR1, the one with
the highest sustained proteinuria value was chosen. This maxi-
mum was named the persistent proteinuria or PP level for the
patient, and the six-month interval chosen, as the PP period.
Values for other potential predictors of CR! were also selected
from the PP period. Creatinine clearance, serum creatinine,
serum albumin, gender, and age were determined at the start of
the interval. In addition, hypertension, treatment, and the slope of
Ccr (derived from a minimum of 3 measurements) were calcu-
lated from all the data in the PP period. The best-fitting logistic
model was developed in the Canadian data set by choosing the
best predictors of CR1. Then, for each patient the risk score (R),
or the probability (P) of progression to CR! can be expressed as
R = P(CRI) = ____
1 + cx
where x is a sum of the chosen covariate values for a patient
multiplied by constants, and e is its exponential.
This new model was applied to each patient in the two
independent data sets obtained from Italy and Finland, and was
compared to our algorithm [281 developed on the Canadian data.
The success of our predictions of CR1 was measured by sensitivity,
specificity, positive predictive value (PPV), negative predictive
value (NPV), and accuracy that is the total proportion correctly
predicted (Appendix 1). These measures were calculated in all
three data sets and compared to the prediction based on: (1)
nephrotic range proteinuria ( 3.5 g/day) at biopsy; (2) persistent
proteinuria of six month lengths of  4 glday,  6 g/day and  8
g/day; and (3) the probability R greater than the chosen cut-off
of  of 0.3.
To further assess the fit of the logistic model to the two
independent data sets, the risk scores (R) were sorted and divided
into quintiles. In each quintile, the number of CR! events
observed was compared to the number of events expected (sum of
the R scores). Pearson's deviance (PC) was then calculated as
PC = sign (observed — expected)
observed # of events — expected # of events
x
expected # of events
If the model fits well, these values can be roughly interpreted as
values from a ,2 distribution with one degree of freedom [31].
Harrell's "C" statistic [32] was also calculated, which is another
measure of the concordance of the data and the prediction.
Random pairs were drawn from the sample, one with CR! and
one without, and the statistic counted the number of times that
the patient with CR1 had the higher risk score.
We examined the length of time from biopsy to start of the PP
period in those patients who developed CR1, versus those who did
not in an attempt to assess the risk of waiting versus early
treatment. We also estimated the influence of variations in the
slope of creatinine clearance on each quintile of the original R
score, since it was expected that this element would have the
greatest potential for error in clinical practice.
Results
The initial demographic and laboratory data from the three
countries are presented in Table 1, and their observation time and
outcomes are presented in Table 2. There were significant differ-
ences observed, including a lower initial creatinine in both the
Finnish and Italian data compared to Canadian patients and a
higher percentage of treated patients in Italy versus the other two
countries. As well, the observation period was longer in Finland
and they had a lower percentage of patients deteriorating to
end-stage renal disease.
The best fitting logistic model derived from the Canadian data
included only three predictors: the persistent proteinuria level,
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Table 1. Demographics and initial laboratory function results from the
three countries
Canada Finland Italy
Sample size, N 184 78 101
Age 42.5 (17) 40.3 (16) 44.9 (15)
Gender % male 66 72 62
Nephrotic at 72 77 83
presentation %
Creatinine mg/dla 1.1 (0.3) 0.9 (O.2)h 1.0 (0.2)'
Creatinine clearance
mI/mini]. 73 m2
94 (25) 107 (24) 98 (31)
Serum albumin g/dl 2.7 (0.8) 2.5 (0.8) 2.4 (0.7)
Proteinuria g/day 6.5 (4.5) 6.9 (5.4) 6.1 (3.6)
Systolic blood pressure 135 (21) 139 (26) N/AC
mm Hg
Diastolic blood pressure 83(11) 85 (14) N/AC
mm Hg

















75 (34) 89 (37) 80 (36)
Serum albumin gidI 3.6 (0.8) 3.3 (0.8) 3.4 (1.0)
Proteinuria g/day 4.12 (5.3) 2.36 (3.2) 2.55 (2.7)
Chronic renal 26 (47) 17 (13) 25 (25)
insufficiency %
(number)
End-stage renal disease 8 (15) 4 (3)C 6 (6)
% (number)
LCcr (final—initial Ccr —19 (37) —18 (30) —18 (37)
mi/mm)
Slope Cr ml/min/1.73 —0.4 (1.2) —0.3 (0.7) —0.3 (1.1)
m2 X month
All data are expressed as mean with so in brackets.
ap = 0.001 vs. Canada and Italy
b To convert to mol/liter, multiply by 88.8
C P 0.01 vs. Canada and Italy
creatinine clearance at the start of the PP period. Therefore, x
becomes
X = K1 + K2 * PP + K3 * (Slope of ocr) + K *
where K1 = 1.26, K2 0.3, K3 = —0.3, and K4 —0.05, and R,
the probability of progressing becomes the exponential of X
divided by I plus the exponential of x. Persistent proteinuria (PP)
is measured in g/day, the slope of Cr in mi/mm per month' and
the initial CC. in mI/mm (Note: to convert to SI units, multiply K3
and K4 by 60 and convert slope term and Cc initial term to
mi/second by dividing by 60). Examples of how to calculate the
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Time, months
Fig. 1. A. Patient A. The maximum sustained proteinuria (*) interval
occurred between months 18 and 24 (12), that is, the PP period, and the PP
value was 3.5 g/day ( ). The initial creatinine clearance (o) at the
start of this interval is 102 mI/mm, and the calculated slope of Cr over this
period was 0 mi/mm/month (... ). The calculated probability of progres-
sion (R) is 0.06 or 6%. B. Patient B. The maximum sustained proteinuria
(*) interval occurred between 0 and six months (L), that is, the PP period,
and the PP value was 12 g/day ( ). The initial creatinine clearance
(o) at the start of this interval was 96 mi/mm and the calculated slope over
this interval was —3 mi/mm/month (. . .). The calculated probability of
progression (R) was 0.72 or 72%. (Note: to convert to SI units multiply K3
and K4 by 60 and convert slope term and Cr initial term to mi/second by
dividing by 60.)
x = K1 +(K2 x PP)+(K3 x slopeofC)+(K4 X Qr1)
x = 1.26 + (0.3 X 3.5) + (—0.3 x 0) + (—0.05 x 102)








All data are expressed as mean with so in brackets.
aTo convert to umol/iiter, multiply by 88.8
hp = 0.01 vs. Canada
C Specific number not available but all patients were classified locally by
same definition as in text
P < 0.00 1 vs. Canada and Finland















PP = 3.5 g/day
Slope of Cr =
102 (final ce,) — 102 (initiai
—
6months






904 Cattran et al: Validation of a prediction model in IMGN







values of Full model(R  0.3)4 glday 6 glday 8 g/day
Sensitivity 93 81 64 58 83
Specificity 38 67 85 93 86
Positive 34 46 59 75 67
predictive value
Negative 94 91 87 87 94
predictive value
Accuracy 52 71 79 84 85
2.6
R — = 0.72
or a 72% chance of progressing.
The test characteristics in regards to predicting CR1 in the
Canadian patients comparing nephrotic range proteinuria at
biopsy, various six-month persistent proteinuria levels, and our
full model using an arbitrary division of R at  0.3 are shown in
Table 3. Inter-country comparisons of the model versus protein-
uria at biopsy  3.5 glday are detailed in Table 4. The accuracy in
the two comparative data sets averaged 87% and 79% compared
to 43% and 34% using the nephrotic syndrome level of protein-
uria at biopsy alone. The overall accuracy of the model, using the
same test characteristics, ranged between 81 and 87% when we
addressed the group divided by ever (N = 187) versus never (N
177) hypertensive and the ever (N = 207) versus never (N = 157)
treated. In the treatment category, the overall accuracy was not
changed by whether the patient received or did not receive
treatment around the PP period, that is, no treatment (N = 139)
accuracy 86%, treatment (N 225) accuracy 83%. When the
Toronto Finland Italy
Chronic renal insufficiency 47/184 (26%) 13/78 (17%) 25/101 (25%)
Sensitivity
Proteinuria >3.5 g/day 93% 100% 84%
Model5 89% 77% 60%
Specificity
Proteinuria >3.5 g/day 38% 30% 17%
Model 86% 89% 92%
Positive predictive value
Proteinuria >3.5 g/day 34% 24% 25%
Model 67% 59% 64%
Negative predictive value
Proteinuria >3.5 g/day 94% 100% 76%
Model 94% 95% 82%
Accuracy
Proteinuria >3.5 g/day 52% 43% 34%
Model 85% 87% 79%
1 2 3 4 5
Quintiles of risk
Fig. 2. The agreement across the five quintiles (1 low, 5 high) of risk of
progression is compared among the three countries (0 Canadian, + Finnish,
* Italian).
patient's slopes were varied by 20%, the expected range of error
in clinical practice, the mean change in the 364 patients in R score
was only 1.2%. When this slope was varied in a more extreme
manner 40%, the mean R score change was 2,3% with the
greatest change in the highest quintile of risk where it was 6%.
The goodness-of-fit (Pearson's Chi-square) over the range of
scores in all three countries was calculated and is illustrated in
Figure 2 [311. There is excellent agreement at the upper and lower
end of the spectrum and good agreement in the mid risk group.
Most of the points on the graph are much smaller than 3.84, the
cut-off for P = 0.05 on a chi-squared distribution with one degree
of freedom. The one point near this value, from Italy, showed a
few more events than predicted in the third quintile. Harrell's "C"
statistic in regards to predicting the higher risk patient when
applied to random pairs was accurate and comparable in all three
countries: Toronto 90%, Italy 89% and Finland 89%. The median
and 75th percentile of the waiting time from biopsy to the start of
the PP period in the three countries in all patients, in those
developing CR1 and in those that do not progress are shown in
Table 5. When only high-risk patients, that is, those who develop
CR1 are examined (Table 6), the percentage whose PP period
Table 3. Test characteristics of predicting chronic renal insufficiency in
Canadian patients
Table 4. Results of model fitting and validation
a At biopsyh R  0.3
ec = 0.06
0.06
R (probability of CR1) =
-j-- = 0.06
or a 6% chance of progressing
Patient B
PP = 12g/day
78 (final Car) — 96 (iflitid.I Car)
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Median 4.3 3.9 4.5
75th Percentile 14.2 11.1 15
Italy
Median 0 6 0
75th Percentile 12 12 8
Finland
Median 3.9 3.7 4.1
75th Percentile 21 11 23
Table 6. Percentage of CR1 patients reaching start of their worst PP








starts within 12 months of biopsy ranges between 72 and 85% in
the three countries.
Discussion
The background of uncertainty of the natural history and hence
the ability to predict outcome has influenced the interpretation
and application of both randomized and non-randomized thera-
peutic studies carried out in patients with IMGN [33—471. The
lack of accord among these studies were a major impetus for our
original model, which was designed to semiquantitate the risk of
progression in these patients. Objections were raised related to its
complexity, the variable observation periods required and its
generalizability. We have simplified the model by restricting the
time frame to six months and have verified the capacity of this new
model to produce an overall accuracy equal to our earlier
approach.
Any model developed and tested in the same data set will
appear to perform well. It is necessary, therefore, to validate the
performance of a new model on data that were not used in the
original set. The most rigorous approach is to test it on a group of
patients with the same disease obtained from another location, as
has been done in other disciplines [48 —52]. lIthe model still works
on patients who may be different for reasons of geography, diet or
treatment practices, this is a strong statement about its robustness.
It is important to recognize that how the patient achieves a
particular R factor is not a factor relevant to the model. It states
only that if patients have certain characteristics in common, their
outcome is going to be similar and that this can be reasonably
predicted. We noted, for instance, that our two comparative data
sets were different from the Canadian one geographically as well
as in some of their initial laboratory features and clinical out-
comes. Despite these differences, the overall accuracy was be-
tween 79% and 87%, very similar to the 85% seen in the Canadian
patients. This accuracy was maintained even when the patients
were separated by whether they had ever been hypertensive or if
they had ever been treated. When we adjusted the slope to assess
the influence of potential error in this element of the model, the
overall effects on the R values were small. Even when the
variation in slope was made extreme (± 40%), the effect observed,
although greater, was really only significant in the high risk group.
It is likely, if this major change in slope was observed in practice,
that a repeat creatinine clearance would be done to ensure that it
was correct. If confirmed, the R value obtained would be appro-
priate in regards to the risk of progression. The good agreement
throughout the range of R scores and the high Harrell's "C"
statistic in all three populations further strengthens the validity of
this approach. The argument that a delay in treatment might
reduce its effectiveness is countered by the recognition that
between 72 and 85% of the high-risk patients reach the start of
their greatest risk period within 12 months of biopsy, and in the
total population, including the low-risk patients, the 75th percen-
tile is reached between 8 and 23 months. Looked at another way,
monitoring the R value carefully over the first one to two years
will usually allow an accurate semiquantitative estimate of any
individual's long-term risk of progression since the values ob-
served during that period in most cases will represent the highest
the patient will ever achieve. This in turn would allow a more
rational discussion with the patient about potential risks and
benefits of the treatment options.
An accurate prediction does require knowing the value of the
four constants plus inputting the laboratory counterparts, but
these functional parameters are readily available, simple, econom-
ical and are utilized worldwide as standard methods of assessment
of patients with serious renal disease. A hand-held calculator with
memory to store the constants plus an exponential function is all
that is required to calculate the R value. Other factors previously
noted to contribute to the risk of progression were included in our
model [1—3, 8—13, 16], but since they did not improve our accuracy
of prediction further they are not required in the algorithm.
Accepting the validity of the model, the following could be its
application to individual patient management. Standard treat-
ment of blood pressure, edema, hyperlipidemia and modest
dietary protein restrictions could be implemented in all patients
with this diagnosis. Regular monitoring of renal function includ-
ing quantitative proteinuria (glday) and C. at regular intervals
would be made over six months. This data would be reviewed and
the patient fitted with an R score. The ultimate choice of therapy
would still be dependent on the physician's judgment and the
patient's wishes, however, for example, in our sample any R
value 0.2 indicates that there is a 20% or less chance of ever
progressing to chronic renal insufficiency. Hence, the patient
could be reassured, symptomatic management maintained and
monitoring reduced appropriately. In contrast, with an R value 
0.8, thus indicating a  80% likelihood of progression, the
therapeutic options and risks of each treatment could be discussed
with the patient and appropriate action taken. For any individual
patient, the percentage from the R score actually indicates the
likelihood of progressing to CR1, for example, in patient A the
risk is 6% and in patient B the risk is 72%. If the R score was in
the mid range, ongoing assessments at 6 to 12 month intervals
could further define and refine the direction of the disease process
for both the patient and the physician. The R value could, using
these rules, impact on future decision-making in regards to both
the timing and type of therapeutic intervention.
Benefits in clinical research trials by the application of the
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algorithm would also be substantial. Patients assessed to be at
similar risk could he entered into appropriate controlled trials.
Although the same number of patients would have to be screened,
there would be a substantial reduction in patients actually allo-
cated to the study yet with the same likelihood of obtaining valid
results. This would not only avoid unnecessary treatment in the
low risk group, but also substantially reduce the overall costs of
the trial.
In summary, in a database of over 360 patients with idiopathic
membranous nephropathy collected from three distinct geo-
graphic regions followed a mean of more than six years, a method
with improved accuracy in predicting outcome in IMGN has been
described, validated, and its potential applications illustrated.
Appendix
Terms used to define a diagnostic test are: (1) positive predictive value
(PPV), probability of having a disease in a patient with a positive test
result; (2) negative predictive value (NPV), probability of not having
disease in a patient with a negative test result; (3) sensitivity (SENS),
probability of having a positive test result in a person with a disease (that
is, true-positive rate); (4) specificity (SPEC), probability of not having a
positive test result in a patient without disease (that is, true-negative rate);
(5) accuracy, the proportion of all the results of a test condition, both
positive and negative, which correctly predicts the disease status.
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